Thu. 21 Mar 2024, 4:03pm ET
Benzinga
Earnings, News
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(1.01) by 29.7 percent. The company reported quarterly sales of $457.00 thousand which beat the analyst consensus estimate of $310.00 thousand by 47.42 percent.